SCHEMBL1706669

SCHEMBL1706669

CC(Br)C(=O)c1ccc(OCC(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
TSHR P16473 1/20 0.55
ALOX15 P16050 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
MAPT P10636 2/20 0.50
MAPK1 P28482 2/20 0.50
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
MCL1 Q07820 1/20 0.47
FFAR1 O14842 1/20 0.47
SRD5A2 P31213 1/20 0.47
MEN1 O00255 1/20 0.46
PTPN7 P35236 1/20 0.46
KMT2A Q03164 1/20 0.46
PTPN12 Q05209 1/20 0.46
CYP19A1 P11511 1/20 0.46
ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14198621 0.86 ALDH1A1 (0.58) ALDH1A1TSHRALOX15SMN1; SMN2MAPT
SCHEMBL7401820 0.84 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL14198615 0.83 ALDH1A1 (0.55) ALDH1A1TSHRALOX15SMN1; SMN2MAPT
SCHEMBL8382724 0.83 ALDH1A1 (0.55) ALDH1A1TSHRALOX15SMN1; SMN2MAPT
SCHEMBL8382728 0.83 ALDH1A1 (0.55) ALDH1A1TSHRALOX15SMN1; SMN2MAPT
SCHEMBL5743825 0.83 PARP10 (0.58) ALDH1A1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL8383676 0.82 ALDH1A1 (0.54) ALDH1A1TSHRALOX15SMN1; SMN2MAPT
SCHEMBL10557960 0.82 ALDH1A1 (0.54) ALDH1A1TSHRALOX15SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL8383678 0.82 ALDH1A1 (0.54) ALDH1A1TSHRALOX15SMN1; SMN2MAPT
SCHEMBL1705733 0.81 ALDH1A1 (0.53) ALDH1A1TSHRALOX15SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572795-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS The University of Chicago (US) 2025-06-25 EP disclosed
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION THE JOHNS HOPKINS UNVERSITY 2025-04-10 US disclosed
US-20240400684-A1 ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-12-05 US disclosed
WO-2024040169-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS THE UNIVERSITY OF CHICAGO (US) 2024-02-22 WO disclosed
US-11484599-B2 Polymer conjugate vaccines THE UNIVERSITY OF CHICAGO (US) 2022-11-01 US disclosed
CN-108770357-B Polymer conjugate vaccines 芝加哥大学 2022-10-28 CN disclosed
US-20220305135-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS THE UNIVERSITY OF CHICAGO (US) 2022-09-29 US disclosed
EP-3976061-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS The University of Chicago (US) 2022-04-06 EP disclosed
CN-114206355-A Methods and compositions for treating cancer with cancer-targeting adjuvants 芝加哥大学 2022-03-18 CN disclosed
US-11219697-B2 Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-01-11 US disclosed
WO-2005068458-A2 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SRC FAMILY PROTEIN KINASE SIRENADE PHARMACEUTICALS AG (DE) 2005-07-28 WO disclosed
US-20050164296-A1 reaction product of a meso-porous organofunctional silica and a ligand; organofunctional silica is prepared from an alkyl silicate and at least one organofunctional silane which contains a group reactive with ligand functional group JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2005-07-28 US disclosed
EP-1360004-B1 CATALYSTS JOHNSON MATTHEY PLC (GB) 2005-05-25 EP disclosed
EP-1360004-A1 CATALYSTS Johnson Matthey PLC (GB) 2003-11-12 EP disclosed
WO-2002066159-A1 CATALYSTS JOHNSON MATTHEY PLC (GB) 2002-08-29 WO disclosed
US-6127191-A SOLID SUPPORT HAVING PLURALITY OF PENDANT SCAFFOLD MOIETIES COVALENTLY ATTACHED; FOR SYNTHESIS OF BIOACTIVE MOLECULES 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-10-03 US disclosed
US-5973188-A Acetic acid derivatives HOFFMANN-LA ROCHE INC. (US) 1999-10-26 US disclosed
WO-1998024760-A1 AMINOBENZENEDICARBOXYLIC ACID-BASED COMBINATORIAL LIBRARIES GRAYBILL TODD L (US) 1998-06-11 WO disclosed
EP-0708751-A1 SYNTHESIS OF COMBINATORIAL ARRAYS OF ORGANIC COMPOUNDS THROUGH THE USE OF MULTIPLE COMPONENT COMBINATORIAL ARRAY SYNTHESES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-05-01 EP disclosed
WO-1995002566-A1 SYNTHESIS OF COMBINATORIAL ARRAYS OF ORGANIC COMPOUNDS THROUGH THE USE OF MULTIPLE COMPONENT COMBINATORIAL ARRAY SYNTHESES ONTOGEN CORPORATION (US) 1995-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11484599-B2 Polymer conjugate vaccines CD14, TLR3, TLR1 ALDH1A1 4596/4885TSHR 1379/4885ALOX15 2767/4885
US-11219697-B2 Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration CTSS, CTSK, CTSF ALDH1A1 3777/4885TSHR 4214/4885ALOX15 1907/4885
US-20220305135-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS TLR3, TLR6, TLR2 ALDH1A1 4206/4885TSHR 2525/4885ALOX15 1380/4885
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION OPRM1, OPRK1, OPRL1 ALDH1A1 2483/4885TSHR 1132/4885ALOX15 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.